Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 07 2023 - 8:30AM
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative
biopharmaceutical company focused on efficiently acquiring,
developing and commercializing or monetizing promising therapeutic
products and product candidates, today announced that Lindsay A.
Rosenwald, M.D., Chairman, President and Chief Executive Officer,
will present a corporate overview at the H.C. Wainwright 25th
Annual Global Investment Conference on Tuesday, September 12, 2023,
at 11:30 a.m. ET. The Company will also attend one-on-one meetings
during the conference.
A webcast and subsequent archived replay of the
company presentation will be available on the Events page of
Fortress’ website under News & Media: www.fortressbiotech.com,
for approximately 30 days following the meeting.
About Fortress BiotechFortress
Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical
company focused on efficiently acquiring, developing and
commercializing or monetizing promising therapeutic products and
product candidates. The company has eight marketed prescription
pharmaceutical products and over 25 programs in development at
Fortress, at its majority-owned and majority-controlled partners
and subsidiaries and at partners and subsidiaries it founded and in
which it holds significant minority ownership positions. Such
product candidates span six large-market areas, including oncology,
rare diseases and gene therapy, which allow it to create value for
shareholders. Fortress advances its diversified pipeline through a
streamlined operating structure that fosters efficient drug
development. The Fortress model is driven by a world-class business
development team that is focused on leveraging its significant
biopharmaceutical industry expertise to further expand the
company’s portfolio of product opportunities. Fortress has
established partnerships with some of the world’s leading academic
research institutions and biopharmaceutical companies to maximize
each opportunity to its full potential, including AstraZeneca, City
of Hope, Fred Hutchinson Cancer Center, St. Jude Children’s
Research Hospital, Nationwide Children’s Hospital and Sentynl. For
more information, visit www.fortressbiotech.com.
Company Contact:Jaclyn JaffeFortress Biotech,
Inc.(781) 652-4500ir@fortressbiotech.com
Media Relations Contact:Tony Plohoros6
Degrees(908) 591-2839tplohoros@6degreespr.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From May 2023 to May 2024